Xenon Pharmaceuticals Inc. XENE
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -16.53%
- 1 year
- -12.33%
- Open
- 37.54
- Prev close
- 37.54
- Mkt cap
- 3.62B
- Vol
- 1.12M
- Avg vol
- 1.51M
- EPS
- -4.74
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 36.84
- High
- 38.12
- Forward P/E
- -7.92
- Beta
- 0.60
- Short ratio
- 2.61
- Inst. own
- 107.44%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 45.79
- 200-d avg
- 52.39
- 1y target
- 71.94
News
2 days ago globenewswire.com
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, BC and BOSTON, MA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical…
-
3 days ago benzinga.com
Xenon Pharmaceuticals Announces Its XEN1701 Surpasses Target Profile; Data Presented During International Association For The Study Of Pain 2026 World Congress On Pain
Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for…
3 days ago globenewswire.com
Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain
XEN1701 achieved target profile, including desired Na V 1.7 receptor occupancy in both the peripheral and central nervous system, and was generally well-tolerated with no notable autonomic…
1 week ago globenewswire.com
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is continuing its investigation into potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ:…
2 weeks ago zacks.com
XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?
Xenon pauses enrollment in late-stage depression trials after unexpected side effects, while its epilepsy pipeline offers growth potential.
2 weeks ago benzinga.com
Full Transcript: Xenon Pharmaceuticals Q2 2026 Earnings Call
Xenon Pharmaceuticals (NASDAQ:XENE) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is…
3 weeks ago benzinga.com
Alpha Buying: 4 Biotech Stocks Insiders Are Betting On
I can sit through a biotech presentation and come away convinced that the company has discovered the answer to half the problems in modern medicine. The slides look terrific. The market opportunity…
3 weeks ago globenewswire.com
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP continues to investigate potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE).
-
3 weeks ago benzinga.com
Guggenheim Assumes Xenon Pharmaceuticals at Buy, Announces Price Target of $73
Guggenheim analyst Delma Caiati assumes Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy rating and announces Price Target of $73.
1 month ago globenewswire.com
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, BC and BOSTON, MA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical…
1 month ago newsfilecorp.com
Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors
Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company…
1 month ago marketbeat.com
Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review
Xenon Pharmaceuticals NASDAQ: XENE said it has filed its first new drug application for azetukalner as a treatment for focal-onset seizures, while pausing portions of its late-stage psychiatry…
1 month ago businesswire.com
XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $XENE--XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law.
1 month ago prnewswire.com
Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)
Analysts cut price targets and reduced their estimates for azetukalner's psychiatric commercial opportunity after Xenon Pharmaceuticals disclosed an enrollment pause in its Phase 3 depression trials…
1 month ago seekingalpha.com
Xenon Pharmaceuticals: Azetukalner Still Has Potential As An Epilepsy Candidate
Azetukalner's focal-seizure application gives Xenon Pharmaceuticals Inc. a potential path to its first commercial revenues, subject to FDA approval. The psychiatry setback weakens expansion…
1 month ago globenewswire.com
Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE).
1 month ago globenewswire.com
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical…
1 month ago proactiveinvestors.com
Xenon Pharmaceuticals falls 30% after depression trial enrollment pause
Xenon Pharmaceuticals Inc. (XENE:NASDAQ) shares were down 30%, on Friday morning after the company voluntarily halted new enrollment in major depressive disorder and bipolar depression studies. The…
1 month ago zacks.com
XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback
Xenon files an FDA application for azetukalner in epilepsy as its depression studies face a temporary enrollment pause.
1 month ago benzinga.com
Xenon Stock Reaction Is Overblown: Analyst
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) submitted a New Drug Application to the U.S. Food and Drug Administration for its investigational drug azetukalner to treat focal seizures.
1 month ago schaeffersresearch.com
Stock Futures Mixed After Thursday's Rebound
Stock futures are mixed after last session's rebound, with several Fed officials scheduled to make remarks
1 month ago benzinga.com
Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining around 150 points on Friday.
1 month ago barrons.com
Xenon Stock Faces Worst Day Since 2017 as Lead Drug Proves a Double-Edged Sword
Xenon Pharmaceuticals says it paused trials for azetukalner in major depressive disorder and bipolar depression following ‘adverse events.'
1 month ago seekingalpha.com
Xenon Pharmaceuticals Inc. (XENE) Discusses Azetukalner NDA Submission for Focal Seizures and Psychiatry Program Update Transcript
Xenon Pharmaceuticals Inc. (XENE) Discusses Azetukalner NDA Submission for Focal Seizures and Psychiatry Program Update Transcript